ESR1 and breast carcinoma: Additionally, our groups and others have identified APOBEC activity as contributing to branched evolution and the acquisition of subclonal mutations later in the evolutionary course of lung adenocarcinoma, estrogen receptor (ER)-negative breast cancer, head and neck squamous cell carcinoma, and esophageal adenocarcinomas [11, 35, 36].